Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 325
- Registration Number
- NCT03377361
- Locations
- 🇺🇸
Local Institution - 0111, Miami, Florida, United States
🇨🇱Local Institution - 0118, Santiago, Región Metropolitana De Santiago, Chile
🇺🇸Local Institution - 0002, Madison, Wisconsin, United States
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
- Conditions
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- St. Justine's Hospital
- Target Recruit Count
- 114
- Registration Number
- NCT03363217
- Locations
- 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦CHU Sainte-Justine, Montreal, Quebec, Canada
🇨🇦CHU de Québec, Quebec City, Quebec, Canada
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2020-12-08
- Target Recruit Count
- 79
- Registration Number
- NCT03352947
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
Dabrafenib and/or Trametinib Rollover Study
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT03340506
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸National Institute Of Health, Bethesda, Maryland, United States
🇺🇸James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT03333343
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
- Conditions
- Metastatic Colon CarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal CarcinomaRAS Family Gene MutationStage III Colon Cancer AJCC v7Stage III Colorectal Cancer AJCC v7Stage III Rectal Cancer AJCC v7Stage IIIA Colon Cancer AJCC v7Stage IIIA Colorectal Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT03317119
- Locations
- 🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States
🇺🇸City of Hope Corona, Corona, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
- Conditions
- Interventions
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 15
- Registration Number
- NCT03299088
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 1
- Registration Number
- NCT03272464
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 40
- Registration Number
- NCT03244956
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 1
- Registration Number
- NCT03232892
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.